Vernakalant
Based on 3 publication(s) in Google Scholar
Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 794466-70-9
- 分子式: C20H31NO4
- 分子量:349.46
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-14183
Vernakalant HydrochloridePotassium Channel Inhibitor -
HY-B0112
MinoxidilEndogenous Metabolite -
HY-100381
Nigericin sodium saltNLRP3 Activator -
HY-15551
E-4031hERG Channels Blocker -
HY-10015
PAP-1Kv1.3 Blocker -
HY-50694
SenicapocGardos Channel Blocker -
HY-12496
NS-1619BK Channel Opener -
HY-B0753
GliclazidePotassium Currents Blocker -
HY-B0112R
Minoxidil (Standard)Endogenous Metabolite -
HY-B0259
IndapamideDiuretic Agent -
HY-12343
ML277Potassium Channel Activator -
HY-B0551
DoxapramTASK-1 Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Vernakalant
More
生物活性
製品説明
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 794466-70-9
-
性状 Solid
-
分子量 349.46
-
分子式 C20H31NO4
-
Color White to light yellow
-
SMILES
COC1=C(C=C(C=C1)CCO[C@H]2[C@@H](CCCC2)N3CC[C@H](C3)O)OC
-
別名
RSD1235
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Stem Cell Res Ther
JAK2 as a surface marker for enrichment of human pluripotent stem cells-derived ventricular cardiomyocytes. [Abstract]2023 Dec 13;14(1):367. PMID: 38093391 -
Clin Pharmacol Ther
Thorough QT/QTc in a Dish: An In Vitro Human Model That Accurately Predicts Clinical Concentration-QTc Relationships. [Abstract]2019 May;105(5):1175-1186. PMID: 30346629 -
J Pharmacol Sci
Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits. [Abstract]2016 Mar;130(3):170-6. PMID: 27032905
プロトコル
-
Two-electrode voltage clamp in Xenopus oocytes
Two-electrode voltage clamp measures whole-oocyte membrane current from Xenopus oocytes expressing exogenous ion channels, receptors, or transporters; one intracellular microelectrode senses membrane voltage, and the second injects current so the amplifier can hold the membrane at command voltages while recording the compensating current as the functional readout. The method is suited to Xenopus oocytes because their large size supports microinjection and intracellular electrode impalement, but the large membrane area can limit voltage-clamp speed and accuracy, especially for large or fast currents.
純度とドキュメンテーション
参考文献
[3]. Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22. [Content Brief]
[4]. Blomstr?m-Lundqvist C, Blomstr?m P.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26. [Content Brief]
[5]. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Cardiovasc Drugs Ther. 2012 Apr; [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Vernakalant 関連分類
HY-14182 関連分類
Powered by Bioz